#	Pagina
attuale pagina	/open-h2020/projects/213669/index.html
-1	/open-h2020/projects/224504/index.html
-2	/open-h2020/projects/214326/index.html
-3	/open-h2020/projects/209990/index.html
-4	/open-h2020/projects/208978/index.html
-5	/open-h2020/projects/200377/index.html
-6	/open-h2020/per-topic/hourly/list/index.html

Opendata, web and dolomites

oWBI

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

oWBI project word cloud

Explore the words cloud of the oWBI project. It provides you a very rough idea of what is the project "oWBI" about.

with body dominated self drugs disease combination force trend onto disposable pressure convenient completion grow business companies lower injection actively class 97m medical assist profit region viscosity migrate optimal wbi mechanical coming competitor licensing nature eco biologically larger closer electronic scj significantly dose segment 2025 successful administration remarkably 86 75 wearable cagr 2020 attractive depending 2015 unlike device 170 wbis medication customization commercialize performance osmotic worn subcuject predictable subcutaneous accumulated synthetic drug sc multiple patient establishing bearing intravenous doses achievement formulations market company bolus profitability paying aps moving paired prefilled strategy ed pharmaceutical deals flexible 9bn seeking injectors ing components

Project "oWBI" data sheet

The following table provides information about the project.

Coordinator	SUBCUJECT APS Organization address address: NORDRE STRANDVEJ 119 city: HELLEBAEK postcode: 3150 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Denmark [DK]
Project website	https://subcuject.com/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-02-01 to 2018-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	SUBCUJECT APS SUBCUJECT APS Organization address address: NORDRE STRANDVEJ 119 city: HELLEBAEK postcode: 3150 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (HELLEBAEK)	coordinator	50˙000.00

Map

Project objective

With more drugs coming onto the market as combination products, i.e. drug products paired with delivery devices pharmaceutical companies are paying closer attention to integrated delivery systems. Due to: 1) the trend in the change in drug formulations, in order to migrate from intravenous to a more cost-effective and convenient subcutaneous (SC) drug administration; and 2) the trend in moving from synthetic derived drugs to biologically drugs that are more complex and have higher viscosity and therefore require delivery of larger doses; resulted in the need for a new class of injection devices - wearable bolus-injectors (WBIs). WBIs are prefilled, disposable devices that are worn on the body of a patient during the SC self-administration of a large dose of medication. The WBI market is estimated to grow in CAGR of 170% between 2015 – 2020 and achieve €6.9Bn by 2025, and pharmaceutical companies are actively seeking for reliable and cost-effective WBIs, providing optimal injection performance at an attractive unit cost and low cost of customization.

Subcuject ApS (SCJ) is a medical device company set to commercialize a new class of WBIs - Subcuject - that makes use of the simple, predictable and strong force of nature: osmotic pressure. Unlike the current WBIs, Subcuject is fully mechanical, bearing no electronic components, resulting in a more flexible, reliable and eco-friendly device at a remarkably lower cost than competitor’s (75 - 86% cost reduction).

SCJ business strategy is based on establishing multiple licensing deals (depending on the drug type, disease, region) with pharmaceutical companies. The Subcuject device is expected to significantly enhance SCJ’s profitability, with an expected accumulated profit of €97M, 5 years after project completion. Moreover, the successful achievement of the project objectives will assist SCJ to be a leading company in the WBI device segment in a market today dominated by U.S. companies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OWBI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OWBI" are provided by the European Opendata Portal: CORDIS opendata.